2023-505925-15-00
Recruiting
Phase 1/2
Phase 1b/2, Multicenter, Open-label, Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3-DXd monotherapy and combinations in Patients with inoperable advanced breast cancer (ABC) after progression on T-DXd- (ICARUS BREAST 2)
Institut Gustave Roussy5 sites in 1 country150 target enrollmentStarted: January 10, 2024Last updated:
Overview
- Phase
- Phase 1/2
- Status
- Recruiting
- Sponsor
- Institut Gustave Roussy
- Enrollment
- 150
- Locations
- 5
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
DRC-PROMOTION- Affaires réglementaires
Scientific
Institut Gustave Roussy
Study Sites (5)
Loading locations...
Similar Trials
Recruiting
Phase 1
Phase 1, open-label, multicenter, dose escalation study of SRG-1505 as monotherapy in subjects with mature b-cell malignancies2023-505204-34-00Schrodinger Inc.22
Recruiting
Phase 1
A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor PatientsNCT07260305Kangabio AUSTRALIA LTD PTY57
Completed
Phase 1/2
Phase 1/2 Study of Belzutifan Plus Palbociclib Versus Belzutifan in Advanced Renal Cell Carcinoma (RCC)2023-504963-17-00Merck Sharp & Dohme LLC76
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMDNCT07275840Innovent Biologics Technology Limited (Shanghai R&D Center)800
Recruiting
Phase 2/3
A Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus BSC versus Placebo plus BSC in Participants with IPSS-R Low- or Intermediate-risk MDS2022-500479-29-00Celgene Corp.166